Apiam Animal Health Limited rejects non-binding indicative offer

Apiam Animal Health Limited (ASX:AHX) has rejected a non-binding indicative offer (NBIO) for the acquisition of 100% of its issued shares. The Board of Directors unanimously determined that the NBIO undervalued the Company, was insufficiently developed, and not in the interests of shareholders.

Board's decision to reject the offer

The Board of Directors of Apiam Animal Health Limited has unanimously rejected the non-binding indicative offer (NBIO) for the acquisition of 100% of the issued shares of Apiam. The Board considered the NBIO undervalued the Company, was insufficiently developed, and not in the interests of shareholders. As a result, the Board has advised the prospective bidder that it does not intend to engage further with them based on the NBIO received.

Outlook and Corporate Strategy

Apiam Animal Health Limited has rejected a non-binding indicative offer (NBIO) for the acquisition of 100% of its issued shares, citing that the offer undervalued the Company and was not in the interests of shareholders. The Company remains committed to providing best in class care for its clients, the animals in their care, and the communities where people live and work. Apiam's purpose, to enrich the lives of animals, people, and communities, is applied across all business operations, reflecting its dedication to excellence in the veterinary and animal health industry.